PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, MD, PhD, Cory Batenchuk, PhD,

Slides:

Advertisements

Similar presentations

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Chee Khoon Lee, PhD, Johnathan Man, M. B. B. S

Quantitative Analysis of Circulating Cell-Free DNA for Correlation with Lung Cancer Survival: A Systematic Review and Meta-Analysis Sarah Cargnin, PhD,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases Jong-Mu Sun, MD, Wei.

Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non–Small Cell Lung Cancer Chao Li, MD, PhD,

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Sunny Guin, PhD, Yuanbin Ru, PhD, Murry W

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project Fred R. Hirsch, MD, PhD,

Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review Swati Kulkarni, MD, Emily T. Vella,

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer Hidenobu Ishii, MD,

Folylpoly-Glutamate Synthetase Expression Is Associated with Tumor Response and Outcome from Pemetrexed-Based Chemotherapy in Malignant Pleural Mesothelioma

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint.

Loss of Phosphatase and Tensin Homolog Protein Expression Is an Independent Poor Prognostic Marker in Lung Adenocarcinoma Naoki Yanagawa, MD, PhD, Charles.

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Relationship between Overall Survival and Response or Progression-Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD-1/PD-L1.

Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas

Prognostic Impact of Newly Proposed M Descriptors in TNM Classification of Non–Small Cell Lung Cancer Junghoon Shin, MD, Bhumsuk Keam, MD, PhD, Miso.

Takehito Shukuya, MD, PhD, David P. Carbone, MD, PhD

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma Steven C. Kao, PhD, Yuen Yee Cheng, PhD,

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases Tao.

Liping Zhang, MD, Hui Yu, MD, PhD, Andrzej Badzio, MD, PhD, Theresa A

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial Kenneth S. Thress, PhD, Vivien.

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature Caicun Zhou, MD, PhD, Luan Di Yao, MD

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

A Comprehensive Analysis of p16 Expression, Gene Status, and Promoter Hypermethylation In Surgically Resected Non-small Cell Lung Carcinomas William.

Diffuse High Intensity PD–L1 Staining in Thymic Epithelial Tumors

Erratum Journal of Thoracic Oncology

Tumor Spread through Air Spaces Affects the Recurrence and Overall Survival in Patients with Lung Adenocarcinoma >2 to 3 cm Chenyang Dai, MD, Huikang.

Natural History and Factors Associated with Overall Survival in Stage IV ALK- Rearranged Non–Small Cell Lung Cancer Jose M. Pacheco, MD, Dexiang Gao,

Appropriateness of Surgical Approach in Black Patients with Lung Cancer—15 Years Later, Little Has Changed Emanuela Taioli, MD, PhD, Raja Flores, MD

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

Impact of HER2 Gene and Protein Status on the Treatment Outcome of Cisplatin-Based Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer

Associations between TS, TTF-1, FR-α, FPGS, and Overall Survival in Patients with Advanced Non–Small-Cell Lung Cancer Receiving Pemetrexed Plus Carboplatin.

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

C-MET/Phospho-MET Protein Expression and MET Gene Copy Number in Non-small Cell Lung Carcinomas Koji Tsuta, MD, PhD, Yoshiki Kozu, MD, PhD, Takahiro.

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Unusual Chemosensitivity of Advanced Bronchioalveolar Carcinoma after Gefitinib Response and Progression: A Case Report Rafal Dziadziuszko, MD, PhD,

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation

Thymidylate Synthase Protein Expression by IHC and Gene Copy Number by SISH Correlate and Show Great Variability in Non–Small Cell Lung Cancer Murry.

SWOG S0709: Randomized Phase II Trial of Erlotinib versus Erlotinib Plus Carboplatin/Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer and.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLC Phil A.J.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer Hui Yu, MD, PhD, Cory Batenchuk, PhD, Andrzej Badzio, MD, PhD, Theresa A. Boyle, MD, PhD, Piotr Czapiewski, MD, Daniel C. Chan, PhD, Xian Lu, MS, Dexiang Gao, PhD, Kim Ellison, MS, Ashley A. Kowalewski, MS, Christopher J. Rivard, PhD, Rafal Dziadziuszko, MD, PhD, Caicun Zhou, MD, PhD, Maen Hussein, MD, Donald Richards, MD, Sharon Wilks, MD, Marc Monte, MD, William Edenfield, MD, Jerome Goldschmidt, MD, Ray Page, DO, PhD, Brian Ulrich, MD, David Waterhouse, MD, Sandra Close, PhD, Jacek Jassem, MD, PhD, Kimary Kulig, PhD, Fred R. Hirsch, MD, PhD Journal of Thoracic Oncology Volume 12, Issue 1, Pages 110-120 (January 2017) DOI: 10.1016/j.jtho.2016.09.002 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 Programmed death ligand 1 (PD-L1) protein expression in SCLC (immunohistochemistry). (A) Positive PD-L1 protein expression in SCLC tumor cells from the extensive-disease SCLC cohort (Dako 28-8). (B) Positive PD-L1 protein expression in tumor-infiltrating immune cells from the limited-disease SCLC cohort (Spring Bioscience SP142). Journal of Thoracic Oncology 2017 12, 110-120DOI: (10.1016/j.jtho.2016.09.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 The bubble plots of Spearman's correlation of programmed death ligand 1 (PD-L1) expression in the limited-disease SCLC Cohort. The size of the bubble is proportional to the number of the repeats at a value. IHC, immunohistochemistry; TIICs, tumor-infiltrating immune cells; C.C, correlation coefficient. Journal of Thoracic Oncology 2017 12, 110-120DOI: (10.1016/j.jtho.2016.09.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Programmed death ligand 1 (PD-L1) messenger RNA (mRNA) in SCLC (SCLC) in situ hybridization (ISH) of the limited disease SCLC cohort. (A) PD-L1 mRNA ISH-positive expression in SCLC tumor cells (original magnification, 600). (B) PD-L1 mRNA ISH-negative expression in SCLC (original magnification, 600). Brown dots in cells represent mRNA expression. Journal of Thoracic Oncology 2017 12, 110-120DOI: (10.1016/j.jtho.2016.09.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Kaplan−Meier survival analysis of overall survival (OS) according to tumor cell membrane staining (immunohistochemistry) of programmed death ligand 1 (PD-L1) in the extensive-disease SCLC cohort. The patients described in this analysis were matched 3:1 (PD-L1 <1 to PD-L1 ≥1) by sex, smoking status (current versus prior/never), and age (dichotomized at 70 years) before analysis for OS by PD-L1 expression. TPS, tumor proportion score; HR, hazard ratio; CI, confidence interval. Journal of Thoracic Oncology 2017 12, 110-120DOI: (10.1016/j.jtho.2016.09.002) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions